RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCIE SCOPUS

      Kynurenine Pathway of Tryptophan Metabolism in Neuropsychiatric Disorders: Pathophysiologic and Therapeutic Considerations

      한글로보기

      https://www.riss.kr/link?id=A107141404

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Under physiological conditions 95% of the ingested essential amino acid tryptophan is metabolized by the kynurenine pathway (KP) to yield the ubiquitous co-enzyme nicotinamide adenine dinucleotide, fulfilling cellular energy requirements. Importantly,...

      Under physiological conditions 95% of the ingested essential amino acid tryptophan is metabolized by the kynurenine pathway (KP) to yield the ubiquitous co-enzyme nicotinamide adenine dinucleotide, fulfilling cellular energy requirements.
      Importantly, the intermediaries of KP exert crucial effects throughout the body, including the central nervous system. Besides, KP metabolites are implicated in diverse disease processes such as inflammation/immune disorders, endocrine/metabolic conditions, cancers and neuropsychiatric diseases. A burgeoning body of research indicates that the KP plays a pathogenic role in major psychiatric diseases like mood disorders and schizophrenia. Triggered by inflammatory processes, the balance between neurotoxic and neuroprotective branches of the KP is disturbed. In preclinical models these discrepancies result in behaviors reminiscent of depression and psychosis. In clinical samples, recent studies are discovering key kynurenine pathway abnormalities which incriminate it in the pathogenesis of the main psychiatric disorders. Harnessing this knowledge has the potential to find disease biomarkers helpful in identifying and prognosticating neuropsychiatric disorders. Concurrently, earnest research efforts directed towards manipulating the KP hold the promise of discovering novel pharmacological agents that have therapeutic value. In this manuscript, an in-depth appraisal of the extant literature is done to understand the working of KP as this applies to neuropsychiatric disorders. It is concluded that this pathway plays an overarching role in the development of major psychiatric disorders, the KP metabolites have the potential to serve as disease markers and new medications based on KP modulation can bring lasting cures for patients suffering from these intractable conditions.

      더보기

      참고문헌 (Reference)

      1 Huang L, "Virus infections incite pain hypersensitivity by inducing indoleamine 2, 3 dioxygenase" 12 : e1005615-, 2016

      2 Laumet G, "Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain" 66 : 94-102, 2017

      3 Badawy AA, "Tryptophan metabolism, disposition and utilization in pregnancy" 35 : e00261-, 2015

      4 Comai S, "Tryptophan in health and disease" 95 : 165-218, 2020

      5 Savitz JB, "Treatment of bipolar depression with minocycline and/or aspirin : an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial" 8 : 27-, 2018

      6 Santana-Martínez RA, "The therapeutic effect of curcumin in quinolinic acid-induced neurotoxicity in rats is associated with BDNF, ERK1/2, Nrf2, and antioxidant enzymes" 8 : 388-, 2019

      7 Rossi F, "The synthesis of kynurenic acid in mammals : an updated kynurenine aminotransferase structural katalogue" 6 : 7-, 2019

      8 Duan KM, "The role of tryptophan metabolism in postpartum depression" 33 : 647-660, 2018

      9 Quan C, "The role of kynurenine pathway and kynurenic aminotransferase alleles in postpartum depression following cesarean section in Chinese women" 10 : e01566-, 2020

      10 Sayson LV, "The novel methoxetamine analogs N-ethylnorketamine hydrochloride(NENK), 2-MeO-N-ethylketamine hydrochloride(2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride(4-MeO-NEK)elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors" 236 : 2201-2210, 2019

      1 Huang L, "Virus infections incite pain hypersensitivity by inducing indoleamine 2, 3 dioxygenase" 12 : e1005615-, 2016

      2 Laumet G, "Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain" 66 : 94-102, 2017

      3 Badawy AA, "Tryptophan metabolism, disposition and utilization in pregnancy" 35 : e00261-, 2015

      4 Comai S, "Tryptophan in health and disease" 95 : 165-218, 2020

      5 Savitz JB, "Treatment of bipolar depression with minocycline and/or aspirin : an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial" 8 : 27-, 2018

      6 Santana-Martínez RA, "The therapeutic effect of curcumin in quinolinic acid-induced neurotoxicity in rats is associated with BDNF, ERK1/2, Nrf2, and antioxidant enzymes" 8 : 388-, 2019

      7 Rossi F, "The synthesis of kynurenic acid in mammals : an updated kynurenine aminotransferase structural katalogue" 6 : 7-, 2019

      8 Duan KM, "The role of tryptophan metabolism in postpartum depression" 33 : 647-660, 2018

      9 Quan C, "The role of kynurenine pathway and kynurenic aminotransferase alleles in postpartum depression following cesarean section in Chinese women" 10 : e01566-, 2020

      10 Sayson LV, "The novel methoxetamine analogs N-ethylnorketamine hydrochloride(NENK), 2-MeO-N-ethylketamine hydrochloride(2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride(4-MeO-NEK)elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors" 236 : 2201-2210, 2019

      11 Mándi Y, "The kynurenine system and immunoregulation" 119 : 197-209, 2012

      12 Worton SA, "The kynurenine pathway; a new target for treating maternal features of preeclampsia" 84 : 44-49, 2019

      13 Favennec M, "The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation" 23 : 2066-2074, 2015

      14 Erhardt S, "The kynurenine pathway in schizophrenia and bipolar disorder" 112 (112): 297-306, 2017

      15 Schwarcz R, "The kynurenine pathway and the brain : challenges, controversies and promises" 112 (112): 237-247, 2017

      16 Savitz J, "The kynurenine pathway : a finger in every pie" 25 : 131-147, 2020

      17 Flis M, "The kynurenic acid hypothesis - a new look at etiopathogenesis and treatment of schizophrenia" 41 : 160-164, 2016

      18 Guloksuz S, "The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway" 48 : 48-52, 2015

      19 Badawy AA, "The end of the road for the tryptophan depletion concept in pregnancy and infection" 130 : 1327-1333, 2016

      20 Suzuki H, "Suicide and microglia : recent findings and future perspectives based on human studies" 13 : 31-, 2019

      21 Meier TB, "Smaller dentate gyrus and CA2 and CA3 volumes are associated with kynurenine metabolites in collegiate football athletes" 33 : 1349-1357, 2016

      22 Agudelo LZ, "Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression" 159 : 33-45, 2014

      23 Steiner J, "Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?" 8 : 94-, 2011

      24 Sakurai M, "Serum metabolic profiles of the tryptophan-kynurenine pathway in the high risk subjects of major depressive disorder" 10 : 1961-, 2020

      25 Chiappelli J, "Salivary kynurenic acid response to psychological stress : inverse relationship to cortical glutamate in schizophrenia" 43 : 1706-1711, 2018

      26 Dantzer R, "Role of the kynurenine metabolism pathway in inflammation-induced depression : preclinical approaches" 31 : 117-138, 2017

      27 Brundin L, "Role of inflammation in suicide : from mechanisms to treatment" 42 : 271-283, 2017

      28 Borsini A, "Rescue of IL-1-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants" 65 : 230-238, 2017

      29 Leday GGR, "Replicable and coupled changes in innate and adaptive immune gene expression in two case-control studies of blood microarrays in major depressive disorder" 83 : 70-80, 2018

      30 Kozak R, "Reduction of brain kynurenic acid improves cognitive function" 34 : 10592-10602, 2014

      31 Gos T, "Reduced microglial immunoreactivity for endogenous NMDA receptor agonist quinolinic acid in the hippocampus of schizophrenia patients" 41 : 59-64, 2014

      32 Lovelace MD, "Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases" 112 (112): 373-388, 2017

      33 Guillemin GJ, "Quinolinic acid, the inescapable neurotoxin" 279 : 1356-1365, 2012

      34 Baranyi A, "Quinolinic acid responses during interferon--induced depressive symptomatology in patients with chronic hepatitis c infection-a novel aspect for depression and inflammatory hypothesis" 10 : e0137022-, 2015

      35 da Silveira TL, "Quinolinic acid and glutamatergic neurodegeneration in caenorhabditis elegans" 67 : 94-101, 2018

      36 Savitz J, "Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder" 40 : 463-471, 2015

      37 Flores-Barrera E, "Preferential disruption of prefrontal GABAergic function by nanomolar concentrations of the α7nACh negative modulator kynurenic acid" 37 : 7921-7929, 2017

      38 Al-Hakeim HK, "Plasma indoleamine-2, 3-dioxygenase(IDO)is increased in drugnaïve major depressed patients and treatment with sertraline and ketoprofen normalizes IDO in association with pro-inflammatory and immune-regulatory cytokines" 19 : 44-54, 2020

      39 Pedersen BK, "Physical activity and muscle-brain crosstalk" 15 : 383-392, 2019

      40 Weyh C, "Physical activity and diet shape the immune system during aging" 12 : 622-, 2020

      41 Dounay AB, "PF-04859989 as a template for structure-based drug design : identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency" 23 : 1961-1966, 2013

      42 Majewski M, "Overview of the role of vitamins and minerals on the kynurenine pathway in health and disease" 67 : 3-19, 2016

      43 Bortz DM, "Oral administration of a specific kynurenic acid synthesis(KAT II)inhibitor attenuates evoked glutamate release in rat prefrontal cortex" 121 : 69-78, 2017

      44 Roman M, "Novel neuroimmunologic therapeutics in depression : a clinical perspective on what we know so far" 83 : 7-21, 2020

      45 Parrott JM, "Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation" 6 : e918-, 2016

      46 Savitz J, "Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder" 52 : 200-211, 2015

      47 Benedetti F, "Neuroinflammation in bipolar depression" 11 : 71-, 2020

      48 Kim YK, "Neuroinflammation and the immune-kynurenine pathway in anxiety disorders" 16 : 574-582, 2018

      49 Buckley PF, "Neuroinflammation and schizophrenia" 21 : 72-, 2019

      50 Romain Troubat, "Neuroinflammation and depression: A review" Wiley 53 (53): 151-171, 2021

      51 Myint AM, "Network beyond IDO in psychiatric disorders : revisiting neurodegeneration hypothesis" 48 : 304-313, 2014

      52 Walker AK, "NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice" 38 : 1609-1616, 2013

      53 Sas K, "Mitochondria, oxidative stress and the kynurenine system, with a focus on ageing and neuroprotection" 23 : 191-, 2018

      54 Li H, "Microglial markers in the frontal cortex are related to cognitive dysfunctions in major depressive disorder" 241 : 305-310, 2018

      55 Laskaris LE, "Microglial activation and progressive brain changes in schizophrenia" 173 : 666-680, 2016

      56 Jacobs KR, "Major developments in the design of inhibitors along the kynurenine pathway" 24 : 2471-2495, 2017

      57 Huang M, "Longitudinal association of inflammation with depressive symptoms : a 7-year cross-lagged twin difference study" 75 : 200-207, 2019

      58 Fujigaki H, "Linking phencyclidine intoxication to the tryptophan-kynurenine pathway : therapeutic implications for schizophrenia" 125 : 1-6, 2019

      59 Walker AK, "Leucine competes with kynurenine for blood-to-brain transport and prevents lipopolysaccharide-induced depression-like behavior in mice" 24 : 1523-1532, 2019

      60 Cervenka I, "Kynurenines: tryptophan’s metabolites in exercise, inflammation, and mental health" 357 : eaaf9794-, 2017

      61 Castro-Portuguez R, "Kynurenine pathway, NAD+synthesis, and mitochondrial function : targeting tryptophan metabolism to promote longevity and healthspan" 132 : 110841-, 2020

      62 Young KD, "Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression" 56 : 335-342, 2016

      63 Bryleva EY, "Kynurenine pathway metabolites and suicidality" 112 (112): 324-330, 2017

      64 Allen AP, "Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression : comparison of multiple ketamine infusions and electroconvulsive therapy" 100 : 24-32, 2018

      65 Braidy N, "Kynurenine pathway metabolism and neuroinflammatory disease" 12 : 39-42, 2017

      66 Garrison AM, "Kynurenine pathway metabolic balance influences microglia activity : targeting kynurenine monooxygenase to dampen neuroinflammation" 94 : 1-10, 2018

      67 Konstantinou G, "Kynurenine pathway in bipolar disorder" 29 : 338-348, 2018

      68 Wu Y, "Kynurenine pathway changes in late-life depression" 235 : 76-81, 2018

      69 Parrott JM, "Kynurenine metabolic balance is disrupted in the hippocampus following peripheral lipopolysaccharide challenge" 13 : 124-, 2016

      70 Albuquerque EX, "Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges" 85 : 1027-1032, 2013

      71 Lim CK, "Involvement of the kynurenine pathway in the pathogenesis of Parkinson’s disease" 155 : 76-95, 2017

      72 Adams S, "Involvement of the kynurenine pathway in human glioma pathophysiology" 9 : e112945-, 2014

      73 Lawson MA, "Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2, 3-dioxygenasedependent depression-like behaviors" 10 : 87-, 2013

      74 Jacobs KR, "Inhibiting the kynurenine pathway in spinal cord injury: multiple therapeutic potentials?" 13 : 2073-2076, 2018

      75 Zakrocka I, "Influence of cyclooxygenase-2 inhibitors on kynurenic acid production in rat brain in vitro" 35 : 244-254, 2019

      76 Achtyes E, "Inflammation and kynurenine pathway dysregulation in post-partum women with severe and suicidal depression" 83 : 239-247, 2020

      77 Connor TJ, "Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?" 441 : 29-34, 2008

      78 Salazar A, "Indoleamine 2, 3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge" 62 : 202-209, 2012

      79 Zoga M, "Indoleamine 2, 3-dioxygenase and immune changes under antidepressive treatment in major depression in females" 28 : 633-638, 2014

      80 Huang X, "Increased plasma kynurenic acid levels are associated with impaired attention/vigilance and social cognition in patients with schizophrenia" 16 : 263-271, 2020

      81 Maes M, "Increased IgA and IgM responses against gut commensals in chronic depression : further evidence for increased bacterial translocation or leaky gut" 141 : 55-62, 2012

      82 Tufvesson-Alm M, "Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons : relevance for schizophrenia" 138 : 130-139, 2018

      83 Wichers MC, "IDO and interferon-alpha-induced depressive symptoms : a shift in hypothesis from tryptophan depletion to neurotoxicity" 10 : 538-544, 2005

      84 Qin Y, "IDO and TDO as a potential therapeutic target in different types of depression" 33 : 1787-1800, 2018

      85 Agus A, "Gut microbiota regulation of tryptophan metabolism in health and disease" 23 : 716-724, 2018

      86 Laurans L, "Genetic deficiency of indoleamine 2, 3-dioxygenase promotes gut microbiota-mediated metabolic health" 24 : 1113-1120, 2018

      87 Alper Evrensel, "Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders" 대한정신약물학회 14 (14): 231-237, 2016

      88 Fallarini S, "Expression of functional GPR35 in human iNKT cells" 398 : 420-425, 2010

      89 Schlittler M, "Endurance exercise increases skeletal muscle kynurenine aminotransferases and plasma kynurenic acid in humans" 310 : C836-C840, 2016

      90 Kehr J, "Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity" 235 : 1593-1607, 2018

      91 Benatti C, "Disease-induced neuroinflammation and depression" 15 : 414-433, 2016

      92 Kanchanatawan B, "Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite(TRYCAT)pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic, and quinolinic acid" 55 : 1524-1536, 2018

      93 Baïlara KM, "Decreased brain tryptophan availability as a partial determinant of post-partum blues" 31 : 407-413, 2006

      94 Pierozan P, "Cytoskeleton as a target of quinolinic acid neurotoxicity : insight from animal models" 55 : 4362-4372, 2018

      95 Zhou Y, "Crosssectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder" 101 : 72-79, 2019

      96 Listunova L, "Cognitive impairment along the course of depression : non-pharmacological treatment options" 51 : 295-305, 2018

      97 Kim BJ, "Clinical insights into the kynurenine pathway in age-related diseases" 130 : 110793-, 2020

      98 Wu W, "Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression : a preliminary study" 7 : 40530-, 2017

      99 Martín-Hernández D, "Chronic mild stress alters kynurenine pathways changing the glutamate neurotransmission in frontal cortex of rats" 56 : 490-501, 2019

      100 Dounay AB, "Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway" 58 : 8762-8782, 2015

      101 Raison CL, "CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha : relationship to CNS immune responses and depression" 15 : 393-403, 2010

      102 Kim H, "Brain indoleamine 2, 3-dioxygenase contributes to the comorbidity of pain and depression" 122 : 2940-2954, 2012

      103 Małyszczak K, "Biological and psychological components of depression in patients receiving IFN-alpha therapy for hepatitis C" 28 : 1217-1222, 2019

      104 Price JB, "Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression" 90 : 212-220, 2018

      105 Baranyi A, "Beta-trace protein as a new non-invasive immunological marker for quinolinic acid-induced impaired blood-brain barrier integrity" 7 : 43642-, 2017

      106 Vallerand IA, "Assessment of a bidirectional association between major depressive disorder and alopecia areata" 155 : 475-479, 2019

      107 Zhou Y, "Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression" 74 : 205-212, 2018

      108 Brundin L, "An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation" 6 : e865-, 2016

      109 Zádori D, "Alzheimer’s disease : recent concepts on the relation of mitochondrial disturbances, excitotoxicity, neuroinflammation, and kynurenines" 62 : 523-547, 2018

      110 Johansson AS, "Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia : cytokine challenge increases production of 3-hydroxykynurenine" 47 : 1815-1823, 2013

      111 Serafini G, "Abnormalities in kynurenine pathway metabolism in treatment-resistant depression and suicidality : a systematic review" 16 : 440-453, 2017

      112 Song P, "Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases" 74 : 2899-2916, 2017

      113 Bay-Richter C, "A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality" 43 : 110-117, 2015

      114 Park LT, "A randomized trial of the N-Methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression" 23 : 417-425, 2020

      115 Condray R, "3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia" 14 : 756-767, 2011

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2022-02-15 학회명변경 영문명 : 미등록 -> Korean College of Neuropsychopharmacology KCI등재
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2013-10-01 평가 등재학술지 선정 (기타) KCI등재
      2012-01-01 평가 등재후보학술지 유지 (기타) KCI등재후보
      2011-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2010-01-01 평가 등재후보 1차 FAIL (등재후보2차) KCI등재후보
      2009-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2007-01-01 평가 SCOPUS 등재 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 1.61 0.26 1.28
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      1.09 0.96 0.376 0.11
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼